Ambrian Hires Leading Life Sciences Equities Team
05 January 2010 - 6:00PM
RNS Non-Regulatory
TIDMAMBR
Ambrian Capital PLC
05 January 2010
Embargoed: 0700hrs, 5 January 2010
Ambrian Capital plc
Ambrian Hires Leading Life Sciences Equities Team
LONDON, 5 January 2010 - Ambrian Partners Limited ("Ambrian"), a wholly-owned
subsidiary of Ambrian Capital plc, has hired a leading life sciences equities
team to be led by Julian Burn-Callander, a former Head of Equity Sales and
founding partner of Code (now Nomura Code) Securities.
Prior to Nomura Code Securities Julian Burn-Callander, who has been in the
equity markets for over thirty years, previously led Healthcare Specialist Sales
at Panmure Gordon and was formerly Head of Equity Sales at SocGen. He will be
joined by three highly experienced life sciences analysts, also founding
partners of Code Securities: Paul Diggle, Mike Ward and Dr Chris Redhead.
Paul Diggle, who has held a number of senior life sciences research positions
including Head of Global Healthcare at S.G. Warburg, will initiate coverage of
European large-cap pharmaceutical companies. Paul will work alongside Mike Ward,
a specialist salesman and analyst who has held positions at both NatWest Markets
and Deutsche Bank. Earlier in his career Mike spent a number of years at Glaxo
Holdings and Sandoz (now Novartis).
Dr Chris Redhead has more than ten years experience providing investment
research of small and mid-cap biotechnology, diagnostics and, more latterly,
biologically-based cleantech companies. He has played a pivotal role in a range
of significant fund-raisings and M&A transactions in the European life sciences
sector and, together with Julian Burn-Callander, will form a strong team focused
on small and mid-cap corporate client opportunities.
Richard Chase, Managing Director of Ambrian Partners, commented,
"Ambrian Partners is seeking to build on its strong market positions in metals &
mining, oil & gas and cleantech by hiring leading teams and individuals in
certain key growth sectors. Julian and the team are very highly respected and
are sure to make an important contribution as we seek to broaden the range of
our specialist sectors. We are delighted to have recruited one of the top
healthcare equities teams in the City."
- Ends -
For further press information please contact:
Richard Chase, Managing Director
Ambrian Partners Limited
+44 (0)207 634 4700
Ben Simons or Charlotte Kirkham
M: Communications
+44 (0)207 920 2340 / 2331
About Ambrian Capital plc
Ambrian Capital (AIM: AMBR) is the holding company of Ambrian Partners Limited,
Ambrian Commodities Limited and Ambrian Metals Limited.
Ambrian Partners Limited is a focused investment bank known in the market today
for its leading positions in the metals & mining, oil & gas and cleantech
sectors. It provides corporate finance advice, equity research, sales and
trading and market making services. Ambrian Partners has been ranked first in
the AIM Basic Materials Sector in the Hemscott Advisers Rankings and was voted
No. 1 for small and mid-cap mining in the Extel Survey of fund managers in 2009.
Ambrian Partners is a member of the London Stock Exchange and is authorised and
regulated by the Financial Services Authority.
For further information on Ambrian Capital, please visit: www.ambrian.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUGURAGUPUGQC
Ambrian Capital (LSE:AMBR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ambrian Capital (LSE:AMBR)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Ambrian (London Stock Exchange): 0 recent articles
More Ambrian Capital plc News Articles